EVH analyst estimates
Evolent Health (EVH) analyst ratings, the average price target and its range, and every firm's latest call.
EVH analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Jul 21, 2026 | Canaccord Genuity | Evolent Health price target raised to $7 from $6 at Canaccord | $7.00 |
| Jun 30, 2026 | Truist Financial | Evolent Health downgraded to Hold from Buy at Truist | $7.00 |
| May 12, 2026 | Canaccord Genuity | Evolent Health price target raised to $6 from $5 at Canaccord | $6.00 |
| Feb 25, 2026 | BMO Capital | Evolent Health (EVH) PT Lowered to $3.50 at BMO Capital | $3.50 |
| Feb 25, 2026 | Truist Financial | Evolent Health price target lowered to $6 from $10 at Truist | $6.00 |
| Feb 2, 2026 | BTIG | Evolent Health price target lowered to $10 from $16 at BTIG | $10.00 |
| Dec 2, 2025 | Piper Sandler | Evolent Health (EVH) PT Lowered to $6 at Piper SandlerMember Login | $6.00 |
| Jan 16, 2025 | UBS | Evolent Health price target lowered to $14 from $27 at UBS | $14.00 |
| Jan 15, 2025 | Truist Financial | Evolent dips after Truist warns guidance may be 'significantly' below consensus | $20.00 |
| Jan 14, 2025 | RBC Capital | Evolent Health (EVH) PT Lowered to $17 at RBC Capital as Membership Declines | $17.00 |
| Jan 10, 2025 | JMP Securities | Evolent Health price target lowered to $18 from $27 at JMP Securities | $18.00 |
| Nov 18, 2024 | Oppenheimer | Evolent Health (EVH) PT Lowered to $28 at Oppenheimer | $28.00 |
| Oct 17, 2024 | Stephens | Evolent weakness linked to elevated Medicaid MLRs at peers, says Stephens | $38.00 |
| Aug 9, 2024 | Truist Financial | Evolent Health upgraded to Buy from Hold at Truist | $33.00 |
| Jun 5, 2024 | RBC Capital | RBC Capital Reiterates Outperform Rating on Evolent Health (EVH) | $42.00 |
- 13 firms rate EVH: 10 buy, 3 hold, 0 sell.
- The average price target is $7.00 from 2 analysts, from $7.00 to $7.00.
Updated 2026-11-05 12:47 UTC